David Demski - Globus Medical President
GMED Stock | USD 50.55 0.18 0.36% |
President
Mr. David M. Demski is appointed as President, Chief Executive Officer, Director of the Company, effective May 31, 2019. He currently serves as Chief Executive Officer, Director of the Company. He served as our President and Chief Operating Officer from August 2008 until September 2015 and as our Chief Financial Officer from 2003 until August 2008. Prior to joining Globus in 2003, Mr. Demski founded Cornerstone Capital LBO Fund, a boutique leveragedbuyout consultancy. Mr. Demskis experience also includes serving as Vice President for Gilo Ventures, a Silicon Valleybased VC fund, from 2000 to 2001, and serving as Chief Operating Officer of Rendall and Associates, a telecommunicationsfocused consulting firm, from 1994 to 2000. He also managed regional and international distribution for Dominos Pizza during the companys growth in the late 1980s. Previously, he was an audit supervisor for Peat, Marwick, Mitchell Company. Mr. Demski received a B.S. in Business Administration from the University of Michigan and an M.B.A. from the Stanford Graduate School of Business since 2019.
Age | 62 |
Tenure | 5 years |
Address | 2560 General Armistead Avenue, Audubon, PA, United States, 19403 |
Phone | 610 930 1800 |
Web | https://www.globusmedical.com |
Globus Medical Management Efficiency
The company has return on total asset (ROA) of 0.0477 % which means that it generated a profit of $0.0477 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0421 %, meaning that it created $0.0421 on every $100 dollars invested by stockholders. Globus Medical's management efficiency ratios could be used to measure how well Globus Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of April 28, 2024, Return On Tangible Assets is expected to decline to 0.04. In addition to that, Return On Capital Employed is expected to decline to 0.03. At present, Globus Medical's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 82.5 M, whereas Return On Tangible Assets are forecasted to decline to 0.04.Management Performance
Return On Equity | 0.0421 | ||||
Return On Asset | 0.0477 |
Globus Medical Leadership Team
Elected by the shareholders, the Globus Medical's board of directors comprises two types of representatives: Globus Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Globus. The board's role is to monitor Globus Medical's management team and ensure that shareholders' interests are well served. Globus Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Globus Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Steve Zarrilli, Independent Director | ||
David Paul, Co-Founder, Chairman, CEO, Chairman of Compensation Committee and Chairman of Nominating and Corporate Governance Committee | ||
Eric Schwartz, Senior Vice President General Counsel | ||
Mike Reeder, Ex Officer | ||
Ann Rhoads, Independent Director | ||
Robert Douglas, Independent Director | ||
Andrew Murphy, Group President Commercial Operations | ||
Steven Payne, VP Controller | ||
Anthony Williams, Senior Vice President General Counsel | ||
Kelly Esq, General VP | ||
Kelly Huller, Senior Vice President General Counsel, Corporate Secretary | ||
Stephen Zarrilli, Independent Director | ||
Robert Liptak, Independent Director | ||
James Tobin, Independent Director | ||
Kurt Wheeler, Independent Director | ||
Brian Kearns, Senior Relations | ||
Brett Murphy, Group President of Commercial Operations | ||
Richard Holifield, Ex Officer | ||
Daniel Lemaitre, Independent Director | ||
John Dowling, Ex Officer | ||
Keith Pfeil, Chief Financial Officer, Senior Vice President | ||
David Demski, Group President of Emerging Technologies, Director and Member of Nominating and Corporate Governance Committee | ||
Daniel Scavilla, Executive Vice President, Chief Commercial Officer and President - Trauma | ||
David Davidar, Co-Founder, Sr. VP of Operations and Director |
Globus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Globus Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0421 | ||||
Return On Asset | 0.0477 | ||||
Profit Margin | 0.08 % | ||||
Operating Margin | 0.13 % | ||||
Current Valuation | 6.85 B | ||||
Shares Outstanding | 112.94 M | ||||
Shares Owned By Insiders | 0.79 % | ||||
Shares Owned By Institutions | 97.40 % | ||||
Number Of Shares Shorted | 7.51 M | ||||
Price To Earning | 73.16 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Globus Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For information on how to trade Globus Stock refer to our How to Trade Globus Stock guide.Note that the Globus Medical information on this page should be used as a complementary analysis to other Globus Medical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Globus Stock analysis
When running Globus Medical's price analysis, check to measure Globus Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Globus Medical is operating at the current time. Most of Globus Medical's value examination focuses on studying past and present price action to predict the probability of Globus Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Globus Medical's price. Additionally, you may evaluate how the addition of Globus Medical to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
CEOs Directory Screen CEOs from public companies around the world | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Globus Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Globus Medical. If investors know Globus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Globus Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.79) | Earnings Share 1.07 | Revenue Per Share 13.87 | Quarterly Revenue Growth 1.246 | Return On Assets 0.0477 |
The market value of Globus Medical is measured differently than its book value, which is the value of Globus that is recorded on the company's balance sheet. Investors also form their own opinion of Globus Medical's value that differs from its market value or its book value, called intrinsic value, which is Globus Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Globus Medical's market value can be influenced by many factors that don't directly affect Globus Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Globus Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Globus Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Globus Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.